Jefferies, which raised its PT on shares of Bio-Rad Laboratories, Inc. BIO, is providing some color on the stock.
“BIO's adjusted 1Q11 EPS of $1.26 was $0.06 below consensus as a higher tax rate and below the line items offset a better than expected revenue growth experience,” Jefferies writes. “We are raising our 2011 EPS forecast to $6.15 (from $6.10). Our price target moves to $145 (from $127) on higher cash flow forecasts.”
Bio-Rad Laboratories closed Tuesday at $126.20.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst Ratingsbio-rad laboratoriesHealth CareJefferiesLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in